Pharma industry backs US inquiry into German reimbursement rules
Seven major pharmaceutical companies and trade groups PhRMA and BIO have publicly endorsed the US Trade Representative's investigation into Germany's new drug pricing measures. They are urging the German government to reconsider certain aspects of these policies, which they argue may hinder market access and innovation. The support signals a coordinated industry push against the pricing framework.
Related stories
Pharma industry personnel changes roundup · Drug development
Drugmakers Race to Market Lp(a) Treatments · Drug development
Large Employers See Health Care Costs Climb · Healthcare systems
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Drugmakers voice support of US probe into Germany’s drug pricing plans.” Browse more stories.